Default Category
-
Cells For Life (B)
John G. Wilson; Robert Young; Georg Oppitz; Wayne Hoy; David BassinCase IVEY-9B09E011-ECorporate Governance, Service and Operations ManagementA biotech company receives umbilical cells for processing. A number of operational improvements are being considered in order to maintain the company's position and reputation in the market. Information on expected delivery dates is known. However, there is a great uncertainty around these dates. The company needs to take account of this variability when arranging for staffing.Starting at €5.74
-
The Abraaj Group and the Acibadem Healthcare Investment (A)
Gompers, Paul A.; Uluduz, Bora; Abacioglu, FirdevsCase HBS-214021-EFinanceThis case concerns the proposed buyout of Acibadem, a leading hospital chain in Turkey. Abraaj, a MENA region private equity firm, proposes to make its first investment in Turkey. The case highlights the role of Turkish health care reform in driving the value. The case provides an opportunity to estimate the potential return on investment as well as evaluate the structuring of the transaction.Starting at €8.20
-
Cells For Life (A)
John G. Wilson; Robert Young; Georg Oppitz; Wayne Hoy; David BassinCase IVEY-9B09E010-ECorporate Governance, Service and Operations ManagementA biotech company receives umbilical cells for processing. A number of operational improvements are being considered in order to maintain the company's position and reputation in the market. Information on expected delivery dates is known. However, there is a great uncertainty around these dates. The company needs to take account of this variability when arranging for staffing. A supporting data set is available, product 7B09E010 for the (A) case...Starting at €8.20
-
The Abraaj Group and the Acibadem Healthcare Investment (B)
Gompers, Paul A.; Uluduz, Bora; Abacioglu, FirdevsCase HBS-214022-EFinanceThis case provides an update on the ultimate outcome of the transaction presented in The Abraaj Group and the Acibadem Healthcare Investment (A).Starting at €5.74